User profiles for Duncan Richards
 | Duncan RichardsVerified email at ndorms.ox.ac.uk Cited by 4252 |
[HTML][HTML] Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an …
…, OA Gbinigie, NM Rahman, G Hayward, DB Richards… - The Lancet, 2023 - thelancet.com
Background The safety, effectiveness, and cost-effectiveness of molnupiravir, an oral
antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the …
antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the …
[HTML][HTML] Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed
With more than 81 000 deaths worldwide from coronavirus disease 2019 (COVID-19) by
April 8, 2020, 1 it is incumbent on researchers to accelerate clinical trials of any readily …
April 8, 2020, 1 it is incumbent on researchers to accelerate clinical trials of any readily …
[HTML][HTML] Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label …
Background A previous efficacy trial found benefit from inhaled budesonide for COVID-19 in
patients not admitted to hospital, but effectiveness in high-risk individuals is unknown. We …
patients not admitted to hospital, but effectiveness in high-risk individuals is unknown. We …
COVID-19 therapeutics: Challenges and directions for the future
The emergence of SARS-CoV-2 triggering the COVID-19 pandemic ranks as arguably the
greatest medical emergency of the last century. COVID-19 has highlighted health disparities …
greatest medical emergency of the last century. COVID-19 has highlighted health disparities …
[HTML][HTML] Therapeutic clearance of amyloid by antibodies to serum amyloid P component
DB Richards, LM Cookson, AC Berges… - … England Journal of …, 2015 - Mass Medical Soc
Background The amyloid fibril deposits that cause systemic amyloidosis always contain the
nonfibrillar normal plasma protein, serum amyloid P component (SAP). The drug (R)-1-[6-[(R)…
nonfibrillar normal plasma protein, serum amyloid P component (SAP). The drug (R)-1-[6-[(R)…
Activation of peroxisome proliferator–activated receptor (PPAR) δ promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty …
…, S Hirschberg, A Liu, Z Fang, P Hegde, D Richards… - Diabetes, 2008 - Am Diabetes Assoc
OBJECTIVE— Pharmacological use of peroxisome proliferator–activated receptor (PPAR)δ
agonists and transgenic overexpression of PPARδ in mice suggest amelioration of features …
agonists and transgenic overexpression of PPARδ in mice suggest amelioration of features …
Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a …
Background Up to 70% of patients with primary biliary cholangitis develop pruritus (itch)
during the course of their disease. Treatment of pruritus in primary biliary cholangitis is …
during the course of their disease. Treatment of pruritus in primary biliary cholangitis is …
Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment
PC Robinson, D Richards, HL Tanner… - The Lancet …, 2020 - thelancet.com
The COVID-19 pandemic continues to wreak havoc on global health-care systems and to
claim an increasing number of lives. Although some treatments have shown promise, including …
claim an increasing number of lives. Although some treatments have shown promise, including …
[HTML][HTML] Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial
…, ID Pavord, S Morgan, D Richards - The Lancet …, 2021 - thelancet.com
Background The antibacterial, anti-inflammatory, and antiviral properties of azithromycin
suggest therapeutic potential against COVID-19. Randomised data in mild-to-moderate disease …
suggest therapeutic potential against COVID-19. Randomised data in mild-to-moderate disease …
[PDF][PDF] The Potential for Repurposing Anti-TNF as a Therapy for the Treatment of COVID-19
Coronavirus disease 2019 (COVID-19) currently has few effective treatments. Given the
uncertainty surrounding the effectiveness and uptake of a vaccine, it is important that the search …
uncertainty surrounding the effectiveness and uptake of a vaccine, it is important that the search …